Intercept Pharma (ICPT) Misses Q4 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals (ICPT) PT Raised to $187 at Raymond James
February 28, 2019 3:02 PM ESTRaymond James analyst Steven Seedhouse raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $187.00 (from $184.00) while maintaining a Strong Buy rating.
Seedhouse said: Bottom line, 1) based on eDISH analysis of the safety population (~2000 patients), there were 3 patients in the... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $130 at RBC Capital
February 28, 2019 2:03 PM ESTRBC Capital analyst Brian Abrahams lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $130.00 (from $137.00) while maintaining a Sector Perform rating.
Abrahams notes the most important takeaway from the call was clarity on potential for liver toxicity, which could... More
Intercept Pharmaceuticals (ICPT) PT Raised to $191 at Cantor Fitzgerald
February 28, 2019 1:59 PM ESTCantor Fitzgerald analyst Alethia Young raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $191.00 (from $170.00) while maintaining a Overweight rating.
Young said the safety update gives them increased confidence.
... More